Assessment of Liver Disease Progression in Cystic Fibrosis Using Transient Elastography. : J Pediatr Gastroenterol Nutr

Archive ouverte

Gominon, A. L. | Frison, E. | Hiriart, J. B. | Vergniol, J. | Clouzeau, H. | Enaud, R. | Bui, S. | Fayon, M. | de Ledinghen, V. | Lamireau, Thierry

Edité par CCSD ; Lippincott, Williams & Wilkins -

International audience. OBJECTIVES: Cystic fibrosis-related liver disease (CFLD) can develop silently in early life and approximately 10% of children with cystic fibrosis (CF) become cirrhotic before adulthood. Clinical, biological, and ultrasound criteria used to define CFLD often reveal liver involvement at an advanced stage. The aim of this retrospective study was to assess the progression of liver stiffness measurement (LSM) in pediatric patients with CF. METHODS: The change of LSM, expressed as kPa/year and %/year, was measured using transient elastography (Fibroscan) in 82 children with CF (median age: 6.8 years, interquartile range [IQR]: 5.8). Mean time interval between the 2 LSM was 3.5 years. RESULTS: Median initial liver stiffness was 3.7 kPa (IQR: 1.3), and then progressed by 0.23 kPa/year, that is, 6%/year. The 7 patients who developed CFLD had a higher initial level of alanine aminotransferase (50 [IQR: 15] vs 30 [IQR: 18], P = 0.0001) and presented a more rapid progression of LSM (0.94 vs 0.23 kPa/year, P = 0.02). CONCLUSIONS: The present study shows that the slope of worsening of liver stiffness is greater in patients who will develop CFLD, suggesting that annual transient elastography may be useful to detect risk of severe liver disease at an earlier stage.

Consulter en ligne

Suggestions

Du même auteur

Erratum à l’article « Nouvelles thérapeutiques de la mucoviscidose ciblant le gène ou la protéine CFTR » [Rev. Mal. Respir. (2016). doi: 10.1016/j.rmr.2015.11.010]

Archive ouverte | Hubert, D. | CCSD

International audience

Increased Fecal Calprotectin Is Associated with Worse Gastrointestinal Symptoms and Quality of Life Scores in Children with Cystic Fibrosis

Archive ouverte | Beaufils, Fabien | CCSD

International audience. In cystic fibrosis (CF), cystic fibrosis transmembrane regulator (CFTR) dysfunction leads to digestive disorders that promote intestinal inflammation and dysbiosis enhancing gastrointestinal ...

Reduced Intestinal Inflammation With Lumacaftor/Ivacaftor in Adolescents With Cystic Fibrosis

Archive ouverte | Tetard, C. | CCSD

International audience. A chronic intestinal inflammation may occur in patients with cystic fibrosis (CF), while no therapeutic management is proposed. Although Lumacaftor/Ivacaftor is well-known to modulate the def...

Chargement des enrichissements...